etodolac has been researched along with Glomerulonephritis, Membranous in 1 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Glomerulonephritis, Membranous: A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 5.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| "This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac." | 1.34 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. ( Aoyama, M; Deji, N; Kashiwagi, A; Kikuchi, K; Nishio, Y; Sakaguchi, M; Sugimoto, T; Uzu, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugimoto, T | 1 |
| Aoyama, M | 1 |
| Kikuchi, K | 1 |
| Sakaguchi, M | 1 |
| Deji, N | 1 |
| Uzu, T | 1 |
| Nishio, Y | 1 |
| Kashiwagi, A | 1 |
1 other study available for etodolac and Glomerulonephritis, Membranous
| Article | Year |
|---|---|
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy, Needle; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Follow-Up Stud | 2007 |